Allstate Corp Takes $545,000 Position in Insulet Co. (NASDAQ:PODD)

Allstate Corp acquired a new stake in Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 2,088 shares of the medical instruments supplier's stock, valued at approximately $545,000.

A number of other large investors have also bought and sold shares of the business. SBI Securities Co. Ltd. bought a new stake in Insulet in the 4th quarter valued at approximately $36,000. SRS Capital Advisors Inc. raised its holdings in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares during the last quarter. TD Private Client Wealth LLC lifted its position in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in Insulet during the fourth quarter worth $57,000. Finally, Assetmark Inc. grew its position in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares in the last quarter.

Insider Activity at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Piper Sandler upped their price objective on Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Citigroup increased their price target on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Canaccord Genuity Group boosted their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Stifel Nicolaus upped their target price on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Finally, Wells Fargo & Company lifted their price target on Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $292.06.

Insulet Price Performance

NASDAQ:PODD traded down $11.54 during trading hours on Friday, hitting $245.26. The stock had a trading volume of 1,337,197 shares, compared to its average volume of 713,775. The company has a 50 day simple moving average of $269.86 and a two-hundred day simple moving average of $259.86. The firm has a market capitalization of $17.22 billion, a price-to-earnings ratio of 42.36, a P/E/G ratio of 3.62 and a beta of 1.30. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a one year low of $160.19 and a one year high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Research analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.